CINECA IRIS Institutional Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishAcipimox (5-methylpyrazine carboxylic acid 4-oxide) is a new inhibitor of lipolysis with long-lasting activity, whose plasma lipid lowering potential was demonstrated in early clinical trials. The hypolipidemic effect of acipimox was investigated in two double-blind cross-over trials versus placebo. The first trial, carried out in 12 type IV patients, showed a significant triglyceride lowering effect (—35%) following 4 weeks of drug administration at a 250 tid dose. The same regimen, maintained for 9 weeks in 18 type IIa patients, failed to induce a significant reduction of total cholesterolemia. However, in 10 subjects, in whom lipoprotein cholesterol fractionation was carried out, a significant reduction of low density and a highly significant increase in high density lipoprotein cholesterol levels (respectively —11% and +20%) were observed
Reduced triglyceridemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis / C. R., Sirtori; G., Gianfranceschi; M., Sirtori; Bernini, Franco; G., Descovich; U., Montaguti; L. M., Fuccella; L., Musatti. - In: ATHEROSCLEROSIS. - ISSN 0021-9150. - 38(3-4)(1981), pp. 267-271. [10.1016/0021-9150(81)90042-3]
| Tipologia ministeriale: | Articolo su rivista | |
| Appare nelle tipologie: | 1.1 Articolo su rivista |
File in questo prodotto:
Copyright © 2021